KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Operating Leases (2020 - 2025)

Vir Biotechnology's Operating Leases history spans 6 years, with the latest figure at $89.1 million for Q4 2025.

  • For Q4 2025, Operating Leases fell 1.2% year-over-year to $89.1 million; the TTM value through Dec 2025 reached $89.1 million, down 1.2%, while the annual FY2025 figure was $89.1 million, 1.2% down from the prior year.
  • Operating Leases for Q4 2025 was $89.1 million at Vir Biotechnology, down from $91.2 million in the prior quarter.
  • Across five years, Operating Leases topped out at $133.6 million in Q4 2021 and bottomed at $66.6 million in Q1 2021.
  • The 5-year median for Operating Leases is $102.1 million (2024), against an average of $104.3 million.
  • The largest annual shift saw Operating Leases surged 392.31% in 2021 before it fell 19.35% in 2024.
  • A 5-year view of Operating Leases shows it stood at $133.6 million in 2021, then dropped by 7.28% to $123.8 million in 2022, then decreased by 9.82% to $111.7 million in 2023, then fell by 19.28% to $90.1 million in 2024, then decreased by 1.2% to $89.1 million in 2025.
  • Per Business Quant, the three most recent readings for VIR's Operating Leases are $89.1 million (Q4 2025), $91.2 million (Q3 2025), and $93.4 million (Q2 2025).